公司資料
IceCure Medical 股價、新聞與催化劑
- 股票代碼:
- ICCM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Israel
股票表現
2.82 USD (-6.62%)
收盤價
最後更新: 2026年8月17日
11.3M USD
市值
股價為何變動
As of Aug 17, 2026, ICCM closed down 6.62% at $2.82. No new same-company headline was identified in the current news window.
公司概覽
Cryoablation Medical Technology
IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal.
ProSense
The ProSense system uses liquid nitrogen-based probes to create a controlled ice ball around a tumor under image guidance.
Breast Cancer Commercialization
FDA clearance supports use in selected early-stage breast cancer patients, providing the foundation for expanded U.S. installations and disposable probe utilization.
Broader Tumor Applications
The platform is also used or studied in kidney, liver, lung, and other tumors accessible to percutaneous cryoablation.
未來催化劑
- The cleaner way to frame IceCure Medical right now is around its latest development priorities. The most useful line from the latest update is and North America May 12, 2026 8:30 am EDT Download as PDF Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as.... That should keep the program at the center of the company narrative for now.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。